Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Semantix Announces Fourth Quarter and Full Year 2022 Financial Results

Published

on

<!– Name:DistributionId Value:8796728 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1260322 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:2af588db-1f9d-4366-9b4d-8e8597d5a9a6 –>

SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) — Semantix, Inc. (NASDAQ: STIX), a leading Latin American end-to-end data and AI platform provider, today announced its financial results for the fourth quarter and the year ended December 31, 2022.

“We believe our positioning at the forefront of emerging data, analytics and AI technologies was reflected in strong Proprietary SaaS revenue growth in the fourth quarter, thus solidifying Proprietary SaaS as a key driver of growth in our business. We plan to accelerate our go-to-market plan with this differentiated offering” said Leonardo Santos, CEO and Founder of Semantix. “We are thrilled with the ongoing innovation in our product portfolio, with newer solutions leveraging data and enabling our customers to develop positive business outcomes, further enhancing their growth potential. With three acquisitions completed since our company’s listing on Nasdaq, we look forward to gaining further momentum and focus on high quality revenues in 2023.”

Fourth Quarter 2022 Financial Highlights

  • Net revenue for the fourth quarter of 2022 was R$96 million, an increase of 132% year-over-year, with relevant increases in each of Semantix’s revenue lines.
  • Proprietary SaaS revenue grew 67% year-over-year.
  • Gross profit increased 167% year-over-year, with gross margin improving 7 percentage points year-over-year to 54% in the fourth quarter of 2022, mainly supported by Proprietary SaaS growth year-over-year.
  • Semantix had 17 customers each contributing more than US$1 million in revenue in 2022.
  • Adjusted EBITDA loss in the fourth quarter was R$26 million, due primarily to ramping investments in talent as well as sales and marketing efforts.
  • Cash and cash equivalents of R$338 million as of December 31, 2022. Net cash (net of the loans and borrowings) was R$ 259 million as of December 31, 2022.

Full Year 2022 Financial Highlights

  • Net revenue for 2022 was R$262 million, an increase of 24% year-over-year, supported by material increases in each of Semantix’s revenue lines.
  • Proprietary SaaS revenue grew 38% year-over-year.
  • Gross profit increased 38% year-over-year, with gross margin improving 5 percentage points year-over-year to 45% in 2022 supported by Proprietary SaaS growth.
  • Adjusted EBITDA loss in 2022 was R$69 million, mainly due to ramping investments in talent as well as sales and marketing efforts.

Fourth Quarter 2022 Key Business Highlights

  • People and leadership: Semantix hired Maurice Mello, a former executive at Google, Microsoft, and SAP, as the new Executive Vice President of Sales and Marketing.
  • Product Development:
    • Launched two relevant new products as part of our proprietary Semantix Data Platform (“SDP”):
      • Semantix Data Marketplace:   Enabling customers to access organized and curated third-party data, significantly increasing our total addressable market in the data marketplace area.
      • Semantix GenAI: an industry-agnostic set of tools designed to streamline the development, training, and deployment of generative AI applications for businesses.
    • Completed integration of the recent acquired Zetta Health platform with the SDP.
    • Updated SDP’s integration module adding 17 new features, improving overall performance and strengthening our low-code product profile.
  • Recent Acquisitions:
    • Elemeno: On February 21, 2023, Semantix completed the acquisition of Elemeno, a US-based, cloud-managed, machine learning operations (MLOps) platform provider. The acquisition aims to enhances Semantix’s MLOps suite of products and expands the company’s presence in the US market strengthening innovation and proprietary technology development capacities, particularly in the area of artificial intelligence and generative AI.
    • ATSaúde: In March 2023, Semantix acquired ATSaúde’s assets, businesses, and operations. ATSaúde specializes in collecting and organizing public databases in the healthcare sector. Its platform processes, organizes, and curates data, generating insights, recommendations, and reports for the pharmaceutical industry and sector organizations.

Fourth Quarter and Full Year 2022 Financial Metrics
(In BRL million, except for percentages)

  4Q 2022 4Q 2021 Y/Y
Change
  2022 2021 Change
Net Revenue R$ 96 R$ 41 132%   R$ 262 R$ 212 24%
Gross Profit R$ 52 R$ 19 167%   R$ 119 R$ 86 38%
Gross Margin 54% 47% 7 pp   45% 41% 4 pp
Adjusted EBITDA (R$ 26) (R$8)   (R$ 69) (R$ 25)
Adjusted EBITDA Margin (27%) (20%) (7 pp)   (26%) (12%) (14 pp)
  Dec 31, 2022 Dec 31, 2021 Change  
Cash and Cash Equivalents R$ 338 R$ 52 548%  
Net Cash (Debt) R$ 259 (R$ 94)  
         

Financial Outlook

Based on current market conditions and management expectations, and subject to a variety of factors described below, Semantix expects that:

  • Proprietary SaaS revenue will be between R$ 75 million and R$ 80 million, implying growth in the range of 40% and 50% in 2023 compared with 2022.
  • Total revenue will increase above 10% compared to the previous year.

Historically, Semantix has received a higher volume of orders from new and existing customers during the second half of the year and, in particular, in the fourth quarter of each year, which we believe is due to, among other factors, the procurement, budgeting, and deployment cycles of many of our customers, particularly large enterprise customers.

Conference Call and Webcast Information

Semantix will host a conference call today, March 28, 2023, at 8:30 a.m. Eastern Time to discuss its financial results and financial outlook. The conference call will be webcast live on Semantix’s Investor Relations website at ir.semantix.ai/news-events/events. Parties interested in participating via telephone may register using this online form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the conference call webcast will be archived on Semantix’s Investor Relations website for at least 30 days.

Forward-Looking Statements

This press release and the earnings call referencing this press release contain forward-looking statements and forward-looking information within the meaning of applicable United States securities legislation that involve substantial risks and uncertainties (collectively herein referred to as “forward-looking statements”). All statements other than statements of historical facts contained in this press release and addressed on our earnings call, including statements regarding our future financial position, results of operations, business strategy and plans and objectives of management for future operations, are forward-looking statements. For example, forward-looking statements include, without limitation, statements concerning the following: the growth of Semantix’s business and its ability to realize expected results, including with respect to its net revenue, gross profit, gross margin, EBITDA, EBITDA margin, adjusted EBITDA, adjusted EBITDA margin, cash and cash equivalents and net cash (debt); the viability of its growth strategy, including with respect to its ability to grow market share in Brazil and internationally, particularly through the expansion of its proprietary SaaS data solutions, grow revenue from existing customers, and consummate and achieve expected benefits through acquisitions; opportunities, trends and developments in the data industry, including with respect to future financial performance in the industry; the size of Semantix’s total addressable market; macroeconomic and geopolitical factors, including as a result of the policies and actions of the new administration in Brazil following the 2022 presidential election. In some cases, you can identify forward looking statements by terminology such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “target,” “trend” or other similar expressions (or the negative versions of such words or expressions).

Such forward-looking statements are based on the current expectations of our management and are inherently subject to uncertainties and changes in circumstance and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements and could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking statements contained in this press release and the earnings call referencing this press release, those results or developments may not be indicative of results or developments in subsequent periods. Although Semantix has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this press release and the earnings call referencing this press release are based on current estimates, assumptions, expectations and projections, including with respect to the management’s expectations regarding Semantix’s growth based on historical financial results and anticipated commercial developments, the anticipated success of current strategies for market penetration in Brazil and globally in light of competition from existing market participants and the emergence of competitors in the future, management’s expectations with respect to the development of technology and other proprietary intellectual property by Semantix based on existing technological realities and strategies with respect to intellectual property development, management’s expectations regarding the likelihood Semantix will be able to enter into commercial arrangements with relevant third-parties and customers, Semantix’s ability to maintain adequate margins based on financial metrics available to management, the ability of Semantix to finance its ongoing capital needs, the continued involvement of Semantix’s management in Semantix’s operations and the ability of Semantix to attract and retain talent in the future, which are based on the information available as of the date of this press release, and, while considered reasonable by Semantix, are inherently uncertain. Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by Semantix. In particular, historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast.

Nothing in this press release and the earnings call referencing this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release and the earnings call referencing this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. This press release also contains certain financial forecast information of Semantix. Such financial forecast information constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive, and other risks and uncertainties. Actual results may differ materially from the results contemplated by the financial forecast information contained in this press release, and the inclusion of such information in this press release should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. You must make your own determinations as to the reasonableness of these projections, estimates, goals, trends and other statements and should also note that if one or more estimates change, or one or more assumptions are not met, or one or more unexpected events occur, the performance and results set forth in such projections, estimates, goals, trends and other statements may not be achieved. We can give no assurance as to future operations, performance, results or events.

WE DO NOT UNDERTAKE ANY OBLIGATION AND EXPRESSLY DISCLAIM ANY RESPONSIBILITY TO UPDATE OR REVISE, OR PUBLICLY DISCLOSE ANY UPDATE OR REVISION TO, ANY FINANCIAL FORECASTS CONTAINED HEREIN TO REFLECT CIRCUMSTANCES OR EVENTS, INCLUDING UNANTICIPATED EVENTS, THAT MAY HAVE OCCURRED OR THAT MAY OCCUR AFTER THE PREPARATION OF THESE FORECASTS. HOWEVER, WE MAY ELECT TO UPDATE OUR BUSINESS OUTLOOK AT ANY TIME FOR ANY REASON.

Non-GAAP Financial Measures

This press release includes certain non-IFRS financial measures (including on a forward-looking basis) and industry metrics such as EBITDA, EBITDA margin, Adjusted EBITDA, Adjusted EBITDA margin  and net cash (debt). These measures are an addition, and not a substitute for or superior to, measures of financial performance prepared in accordance with IFRS and should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with IFRS. Semantix believes that these measures (including on a forward-looking basis) provide useful supplemental information to investors about Semantix, particularly as they exclude the impacts of certain events that we believe are isolated in nature incurred as part of our recent expansion and, therefore, not reflective of our underlying results. Semantix’s management does not consider these non-IFRS measures in isolation or as an alternative to financial measures determined in accordance with IFRS. Semantix’s management uses forward-looking non-IFRS measures to evaluate Semantix’s projected financials and operating performance. However, there are a number of limitations related to the use of these measures, including that they exclude significant expenses that are required by IFRS to be recorded in Semantix’s financial statements, including certain research expenses, provisions, expenses related to our stock option plans and other expenses related to our expansion, including our recently-completed business combination and other acquisitions. In addition, other companies may calculate non-IFRS measures or industry metrics differently or may use other measures to calculate their financial performance, and therefore, Semantix’s non-IFRS measures and industry metrics may not be directly comparable to similarly titled measures of other companies. Additionally, to the extent that forward-looking non-IFRS financial measures are provided, they are presented on a non-IFRS basis without reconciliations of such forward-looking non-IFRS measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations.

Other Business Metrics

Proprietary SaaS and Resale of Third-party Software: Proprietary SaaS consists of Semantix’s data platform software, while Resale of third-party Software consists of the resale of licenses from third-party data platform software providers.

Customers with Trailing 12-Month Revenue Greater than US$1 Million: Large customer relationships lead to scale and operating leverage in our business model. Compared with smaller customers, large customers present a greater opportunity for us to sell additional capacity because they have larger budgets, and a wider range of potential use cases. As a measure of our ability to scale with our customers and attract large enterprises, we count the number of customers that contributed more than US$1 million in revenues in the trailing 12 months, considering the Brazilian real to US Dollar exchange rate as of December 31, 2022. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity.

Net Cash (Debt): Net cash (debt) reflects Semantix’s cash and cash equivalents balance at a given date in time, net of the loans and borrowings balance as of the same date.

About Semantix

Semantix is Latin America’s first fully integrated data software platform. Semantix has more than 300 clients with operations in approximately 15 countries using Semantix’s software and services to enhance their businesses. The company was founded in 2010 by CEO Leonardo Santos. For more information, visit www.semantix.ai.

Semantix Inc.
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (1)
(in BRL thousands)

  Three Months Ended, Year Ended,
  December 31 December 31
  2022 2021 2022 2021
Revenues 95,914 41,360 262,094 211,659
Cost of sales (43,971) (21,917) (143,327) (125,454)
Gross profit 51,943 19,443 118,767 86,205
Operating expenses        
Sales and marketing expenses (32,059) (14,161) (70,355) (36,693)
General and administrative expenses (51,266) (21,821) (115,544) (81,522)
Research and development (8,468) (18,555) (33,160) (19,920)
Listing expenses (215,570)
Other expenses (19,290) 210 (35,032) (9,205)
Operating loss (59,140) (22,599) (350,894) (61,135)
         
Financial income 25,060 3,530 54,962 6,528
Financial expenses (11,050) (7,423) (42,542) (21,508)
Net financial results 14,010 (3,893) 12,420 (14,980)
         
Loss before income tax (45,130) (26,492) (338,474) (76,115)
Income tax 970 503 8,644 7,741
Loss for the period / year (44,160) (25,989) (329,830) (68,374)

(1)   The financial information contained in this earnings release has been audited by our external auditors and prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). However, such financial information has not yet been audited by our external auditors in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB), which will be required in connection with the preparation of our 2022 annual report on Form 20-F, but is not yet complete. Accordingly, the financial information included in this earnings release is subject to change based on the completion of PCAOB procedures and further adjustments may be necessary to fully conform with PCAOB rules and standards.

Semantix Inc.
Condensed Consolidated Statement of Cash Flows (1)
(in BRL thousands)

  Year ended
  December 31,
  2022 2021
Loss for the year (329,830) (68,374)
Adjustments to reconcile loss for the year    
Depreciation and amortization 17,816 7,950
Deferred income tax (9,639) (7,741)
Onerous contract (7,772) 7,745
Fair value adjustment of derivatives financial instruments (23,193) (1,308)
Stock option plan 4,025 7,757
Listing expense 215,570
Loss on disposals of property and equipment 90
Trade and other receivables expected loss 15,320 8,950
Accounts receivable write-off and Write-off of creditor invoice (4,885) 9,415
Provision for contingencies 3,942 6,148
Interest accrued 29,070 11,340
Interest paid (29,268) (5,116)
Change in operating assets and liabilities (92,161) 6,840
Net cash outflow from operating activities (211,005) (16,304)
Purchase and development of intangible assets (36,936) (21,249)
Acquisition of subsidiaries net of cash acquired (24,143)
Acquisitions of property and equipment (498) (618)
Net cash outflow from investment activities (61,599) (21,867)
Proceeds from exercise of stock options 276
Proceeds from non-controlling interest 5,018
Loans obtained 122,015 120,175
Acquisition of non-controlling interest (47,888)
Payment of loans (189,514) (9,843)
Proceeds from SPAC merger, net 630,083
Purchase of treasury shares (508)
Lease payments (1,400) (1,160)
Net cash inflow from financing activities 560,952 66,302
Increase in cash and cash equivalents 288,348 28,131
Cash and cash equivalents at the beginning of the year 52,149 25,936
Cash and cash equivalents at the end of the year 338,020 52,149
Effect of exchange rate changes (2,477) (1,918)
Increase in cash and cash equivalents 288,348 28,131
     
Supplemental non-cash flow information    
New lease agreements 1,728
Remeasurement of lease agreement 211 (411)
Unpaid amount related to business combination 33,062 4,959
Other receivables related to the sale of non-controlling interest 5,018

(1)   The financial information contained in this earnings release has been audited by our external auditors and prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). However, such financial information has not yet been audited by our external auditors in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB), which will be required in connection with the preparation of our 2022 annual report on Form 20-F, but is not yet complete. Accordingly, the financial information included in this earnings release is subject to change based on the completion of PCAOB procedures and further adjustments may be necessary to fully conform with PCAOB rules and standards.

Semantix Inc.
Condensed Consolidated Statement of Financial Position (1)
(in BRL thousands)

  December 31, 2022 December 31, 2021
ASSETS    
Cash and cash equivalents 338,020 52,149
Trade receivables and other, net 139,546 36,525
Tax receivables 11,317 4,993
Prepaid expenses and other assets 35,060 18,603
PP&E, Intangible and right of use asset 156,110 81,159
Deferred tax asset 22,488 11,698
Derivatives financial instruments 1,308
Total current assets 519,169 111,686
Total non-current assets 183,372 94,749
Total assets 702,541 206,435
     
LIABILITIES    
Loans and borrowings 78,671 146,594
Trade and other payables 106,023 78,389
Lease liabilities and other liabilities 66,348 34,459
Taxes payable 14,733 3,859
Derivatives financial instruments 6,412
Deferred income tax 8,929 7,029
Total current liabilities 181,390 142,030
Total non-current liabilities 99,726 128,300
Total liabilities 281,116 270,330
     
EQUITY    
Share capital 425 55,818
Additional paid-in capital 872,771
Capital reserves 20,300 15,999
Other comprehensive income (6,840) (1,022)
Treasury shares (508)
Accumulated loss (468,869) (140,477)
Non-controlling interests 4,146 5,787
Total equity 421,425 (63,895)
Total equity + liabilities 702,541 206,435

(1)   The financial information contained in this earnings release has been audited by our external auditors and prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). However, such financial information has not yet been audited by our external auditors in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB), which will be required in connection with the preparation of our 2022 annual report on Form 20-F, but is not yet complete. Accordingly, the financial information included in this earnings release is subject to change based on the completion of PCAOB procedures and further adjustments may be necessary to fully conform with PCAOB rules and standards.

Semantix Inc.
GAAP to Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin Reconciliations (9)
(in BRL thousand)

  Three Months Ended,
December 31,
  2022 2021
Loss for the period (28,488 ) (25,993 )
(+/-) Net interest income (expenses) (8,089) 4,550
(+/-) Income tax (970) (482)
(+) Depreciation and amortization 5,791 3,154
EBITDA (31,756 ) (18,771)
(+) Data platform relaunch research expenses (1)
(+) Stock option expenses (2) 2,825 3,738
(+) Transaction expenses (3) 3,634 6,662
(+) Listing expenses (4)
(+) D&O Expenses (5) 7,720
(+) Earn-out payment expenses (6)
(+) Onerous contract provision expenses (7)
(+/-) Fair Value of Derivative Financial Instruments (8) (8,777)
Adjusted EBITDA                               (26,354 ) (8,371 )
Net Revenue  95,914  41,361
Adjusted EBITDA Margin -27% -20%
  Year Ended,
December 31,
  2022 2021
Loss for the period (329,830 ) (68,374 )
(+/-) Net interest income (expenses) 6,233 9,427
(+/-) Income tax (8,644) (7,720)
(+) Depreciation and amortization 18,211 8,009
EBITDA (314,030) (58,658)
(+) Data platform relaunch research expenses (1) 1,054
(+) Stock option expenses (2) 6,830 13,438
(+) Transaction expenses (3) 40,551 6,662
(+) Listing expenses (4) 215,569
(+) D&O Expenses (5) 7,722
(+) Earn-out payment expenses (6) 4,858
(+) Onerous contract provision expenses (7) 7,745
(+/-) Fair Value of Derivative Financial Instruments (8) (25,660)
Adjusted EBITDA                               (69,017) (24,900)
Net Revenue  262,094  211,655
Adjusted EBITDA Margin -26% -12%

(1)   Consists of isolated research expenses incurred in 2021 in connection with the redesign and relaunch of Semantix’s proprietary data platform with the purpose of enhancing its functionality.
(2)   Consists of expenses related to stock option grants under our 2021 stock option plan and a stock option plan adopted by us in 2020, including payroll expenses in the amounts of R$2.8 million and R$0.7 million for the twelve-month periods ended December 31, 2022 and 2021, respectively.
(3)   Consists of concentrated expenses of an extraordinary nature related to third-party advisory, support services, travelling and events incurred in connection with our business combination with a SPAC that are not expected to be ongoing.
(4)   Consists of a one-time non-cash expense reflecting the accounting impact of the NASDAQ listing in accordance with IFRS 2.
(5)   Consists of expenses related to D&O Insurance (directors’ and officers’ liability insurance).
(6)   Consists of expenses related to earn-out payment to the former shareholders of LinkAPI.
(7)   Consists of non-cash expenses recorded in 2021 under provisions relating to the early termination by a single client of a three-year contract to purchase third-party software in the early phases of Semantix’s U.S. operations, with such amount corresponding to Semantix’s ongoing payment obligations under an onerous contract with the third-party software supplier despite the early termination of the resale contract by Semantix’s client.
(8)   Consists of gains from fair value of Semantix Warrants.
(9)   The financial information contained in this earnings release has been audited by our external auditors and prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB). However, such financial information has not yet been audited by our external auditors in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB), which will be required in connection with the preparation of our 2022 annual report on Form 20-F, but is not yet complete. Accordingly, the financial information included in this earnings release is subject to change based on the completion of PCAOB procedures and further adjustments may be necessary to fully conform with PCAOB rules and standards.

Investor Contact
Adriano Alcalde
Chief Financial Officer & IR
[email protected]

Press Contact
[email protected]

Source: Semantix, Inc

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Ancoris Recognised as Top Place to Work for Second Year Running by The Sunday Times

Published

on

ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times

Ancoris recognised for fostering a sense of empowerment and respect within the workplace91% of Ancoris employees feel empowered at work93% of employees say that are treated with respectLONDON, May 21, 2024 /PRNewswire/ — Ancoris, a UK-based Google Cloud services provider, has been named a Top Medium Business in The Sunday Times 2024 Best Places to Work list. The accolade has been awarded for the second year in a row, and recognises Ancoris’ focus on DEI; its commitment to empowerment, reward, and recognition; and its wellbeing policies and frameworks.

“I am so pleased to see Ancoris recognised, once again, as a top place to work!” says Andre Azevedo, Ancoris CEO. “Ancoris is a place where we try our best to foster collaboration, empowerment, innovation, and respect – so to have our employees echo this and respond in the way they have is amazing.”
The Sunday Times survey captured Ancoris employees’ responses in a number of categories: Reward and Recognition, Information Sharing, Empowerment, Wellbeing, Instilling Pride, and Job Satisfaction. The independently managed survey showed Ancoris scoring “excellent” across all six engagement categories, with top scores in Empowerment, Wellbeing, Reward & Recognition. In response, 93% of employees say they are treated with respect; 92% feel trusted and able to make decisions; and 91% of employees feel empowered at work.
“We’ve seen a lot of change over the last 12 months. The rise of Generative AI has caused shifts in our market and  economic conditions are causing customers to really qualify where they make technology investments. These pivots undoubtedly have an impact on our employees and how people feel at work,” Azevedo continues. “I truly believe, however, the innovative work we are doing for our customers has helped us maintain and create an even stronger sense of collaboration and pride for our team members. We’re lucky to have so many smart people within our business, so continuing to give them interesting, challenging, and rewarding problems to solve for our customers is really key.”
About AncorisAncoris is a leading Google Cloud Services Provider, headquartered in the UK, on a mission to become the most innovative Google Cloud partner in the ecosystem. Ancoris leverages its strong problem solving skills and continuous improvement approach to help customers become AI Native and stay ahead of their competition. Ancoris has extensive experience in Google Cloud technologies helping enterprises integrate AI-native solutions into their business through expertise in Data & AI, Application and Infrastructure Modernisation, Workspace, and Maps. Ancoris was recognized as a Rising Star for Data, Analytics, and Machine Learning in the ISG Provider™ Lens for Google Cloud Partner Ecosystem in 2022 and 2023 consecutively, and awarded Google Cloud’s 2024 EMEA Public Sector Partner of the Year award. Ancoris employs the best in the business and was named in the Top 10 Sunday Times Best Places to Work 2023, and a Top Place to Work in 2024.
Contact: Holly [email protected]
Photo – https://mma.prnewswire.com/media/2417995/Ancoris_Sunday_Times.jpgLogo – https://mma.prnewswire.com/media/2099949/4717512/Ancoris_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ancoris-recognised-as-top-place-to-work-for-second-year-running-by-the-sunday-times-302151325.html

Continue Reading

Artificial Intelligence

Department of Health – Abu Dhabi Partners with Roche Pharmaceuticals Middle East to Elevate Research, Clinical Trials, and Real-World Data

Published

on

department-of-health-–-abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research,-clinical-trials,-and-real-world-data

ABU DHABI, UAE, May 21, 2024 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle East during Abu Dhabi Global Healthcare Week (ADGHW). Under the MoU, the two entities will advance critical research using real-world data to study and assess the spinal muscular atrophy burden in Abu Dhabi, as well as assessing potential conduction of research and the facilitation of real-world data collection to monitor Duchenne Muscular Dystrophy (DMD) disease.

 
 
In the presence of Dr. Rashed Alsuwaidi, the Executive Director of the Healthcare Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center at the at DoH said: “Abu Dhabi has a track record of excellence and fast-growing, future-forward, data-enabled services. Serving as a hub for healthcare data, Abu Dhabi’s substantial computing power enables it to harness the potential within this data, transforming it into valuable information. This, in turn, allows us to innovate and develop novel approaches to shift healthcare towards prediction, prevention, and treatment, thereby accelerating the future of healthcare, not only for Abu Dhabi but for the global community. Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as expand access to quality care for patients around the world.”
The two entities will work together to support the evolution of real-world data collection frameworks in Abu Dhabi. Enhancing DoH’s ability to track and monitor outcomes of therapies will support DoH in making informed clinical and policy decisions for better optimisation of patient outcomes. Furthermore, DoH and Roche will strengthen the research network across Abu Dhabi and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General Manager Roche Pharmaceuticals, UAE said: “This MoU underscores our collaboration with the DoH which is fuelled by a shared vision of harnessing the power of data to drive informed decision-making within the healthcare system. Data-driven healthcare systems hold immense potential to revolutionise patient care and outcomes. Through the generation, utilisation, and realisation of data, healthcare professionals and policymakers can unlock valuable insights, identify trends, and make evidence-based decisions. This data-driven approach enables us to optimise resource allocation, personalise treatment approaches, and ultimately achieve better patient outcomes. By harnessing the full potential of data, we can improve the overall efficiency and effectiveness of the healthcare system, ensuring that every patient receives the highest quality of care tailored to their specific needs. We are sincerely grateful for the trust, confidence, and empowerment the DoH has placed in establishing this effective public-private partnership with Roche in the UAE.”
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, ADGHW is a major government initiative by the DoH, which took place from the 13th -15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
Photo – https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/department-of-health–abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html

Continue Reading

Artificial Intelligence

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe

Published

on

biopharma-leaders-shape-the-future-of-drug-development-at-veeva-r&d-and-quality-summit-europe

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes
BARCELONA, Spain, May 21, 2024 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.
The event’s zone keynotes include:
Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.Novo Nordisk, showing how it uses data and AI to transform clinical research.Sanofi, explaining its innovative approach to advance quality through operational excellence.Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.
“Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients,” says Rik Van Mol, senior vice president of Veeva Development Cloud. “At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together.”
Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.
Additional InformationConnect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Jeremy WhittakerVeeva [email protected]
Logo – https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html

Continue Reading

Trending